April and May have brought a wave of news that highlights the widening gap between progress and pressure in health systems across the world.
In the UK, a medical milestone captured headlines as Grace Davidson became the first woman in the country to give birth following a womb transplant. The donor? Her sister.
The procedure's success offers new hope to women living with uterine infertility and marks a significant advance in reproductive medicine.
But even as medicine moves forward, the NHS is facing hard decisions. With a projected £6.6 billion deficit, hospitals across England are undergoing what’s being called a "financial reset", which involves cutting staff, closing services, and scaling back beds in areas like rehabilitation and palliative care.
At the same time, the Health Foundation has warned that the UK will need to invest around £21 billion over the next five years just to bring NHS and adult social care systems up to digital standards.
That includes everything from integrated health records to modern IT infrastructure, critical upgrades for a system under immense strain.
Meanwhile, fresh concern has emerged over gender equality in medical research. Experts say there’s a "concerning” lack of female-only clinical trials in the UK, leaving large gaps in evidence for how drugs and treatments impact women specifically. It’s an issue that’s gaining more attention as the industry pushes toward more inclusive, personalised care.
Internationally, healthcare has also felt the shockwaves of shifting U.S. aid policy. UNICEF has warned that cuts in funding are disrupting childhood vaccination programmes across multiple countries, to an extent comparable with pandemic-era setbacks. In South Africa, the impact is already being seen in HIV testing rates, which have fallen sharply, especially among pregnant women and babies.
In the U.S., a different kind of policy is drawing scrutiny. A proposed 25% tariff on imported drugs could cost the country an estimated $51 billion a year, according to recent analysis.
Critics warn the move would not only raise prices but also restrict access to essential treatments for many Americans.
Amid these challenges, there are promising developments. Weight-loss drugs like Ozempic and Wegovy, originally developed for diabetes and obesity, are now showing promise in reducing the risk of heart disease and even extending life expectancy. It’s part of a wider shift toward using metabolic therapies to treat chronic disease more broadly.
And in India, the Punjab Health Department is doubling down on community health. It has relaunched Village Health, Sanitation, and Nutrition Committees in a bid to boost disease prevention and public health efforts at the local level, particularly around mosquito-borne illnesses and nutrition.
It’s a reminder that health isn’t just about hospital beds or blockbuster drugs, it’s about infrastructure, investment, equity, and political will. And as April and May’s stories show so far, the stakes are high and rising.
You can read the full newsletter here.